This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
London, 25/10/2023: The pharmaceutical industry is currently responsible for over four per cent of global carbon emissions and this figure is on track to grow in the coming years. Here Simon Farnfield, event director at Lab Innovations, discusses the changes that are allowing the pharmaceutical industry to go green at last.
The pharmaceutical and biotechnology industries are heavily regulated, and navigating these regulations can be a significant challenge for companies, especially those with limited experience. Additionally, they can provide support during FDA inspections and audits, ensuring that companies are well-prepared for these critical events.
In May 2025, Altasciences attended CPHI Americas in Philadelphia, where industry leaders, innovators, and stakeholders gathered to explore the latest advancements in pharmaceutical development technologies and connect with providers. Events like this remind us why innovation thrives on collaboration. Why does that matter?
In the lead up to the inaugural launch of Connect In Pharma, co-founder Wilfried Phipps provides insight into what visitors can expect at this new annual event designed to help shape the future of pharmaceutical packaging and manufacturing projects
HP&M is proud to have our professionals participating in these important events. His practice supports clients throughout the life sciences from biotech startups and multinational pharmaceutical companies to CROs and academic researchers to patient advocacy organizations. We can offer our readers a special discount for the event.
The Life Sciences Commercial Contracts and Chargebacks conference returns as a hybrid event May 24-25 with the options of attending in-person in Philadelphia or virtually. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). Save 10% by using code 22DC10.
Most adverse events (AEs) were mild to moderate in severity. Biogen emphasized that no dose-limiting toxicities were observed, and there were no reports of serious adverse events directly attributable to the study drug. Both the 40 mg and 80 mg doses of salanersen were generally well-tolerated , with no new safety signals identified.
The upcoming Pharma IQ Live: SmartLab Digital 2022 conference will bring together an impressive group of pharmaceutical and technology leaders including Merck, Pfizer, GSK, and more. Strateos is pleased to be participating alongside industry peers to discuss Lab 4.0 solutions to overcome common challenges in drug discovery workflows.
Revolutionizing Generic Drug Development: The Power of Digital Transformation As the pharmaceutical industry continues to evolve, one thing is clear: digital transformation is no longer a luxury, but a necessity. AI-powered tools can accelerate development times, reduce costs, and improve product quality.
This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. And of course, I'll be there to moderate the entire event and lead the fireside chats. Thanks to DCI’s partnership with HMP Global, we can bring this novel event to the drug channels community.
Advancing drug candidates across key therapeutic areas Dr John Donello brings over 25 years of experience in pharmaceutical drug discovery, development and collaborations. Event-driven pharmacology Donello highlights the growing recognition of synaptic plasticity’s crucial role in the biology of depression.
(HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico. HPM is a co-sponsor of the event. The event is hosted by by Porzio, Bromberg & Newman. To register, please use this link.
Come together with leaders from the pharmaceutical, biotechnology, and diagnostic industries to unpack huge changes at the American Conference Institutes 23rd Advanced Summit on Life Sciences Patents , which is scheduled to take place from May 19-20, 2025 at the New York Bar Association in New York, NY. The discount code is: D10-999-FDA25.
For pharmaceutical companies, this shift presents both challenges and opportunities. In today's digital age, social media has transformed how businesses communicate with their audiences. Social media can significantly enhance brand visibility and patient engagement and have an impact on the overall healthcare sector.
Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this years event focussed on drugging the undruggable.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. This event is part of The Drug Channels 2025 Video Webinar Series.
Hybrid Event In-Person: November 17-19, 2021 in Philadelphia Virtual: November 22-23, 2021 www.informaconnect.com/gtn. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). Informa Connect's Pharma/Biotech GTN Summit. Plus, in-person participation qualifies for CPE credits!
of participants reported treatment-emergent adverse events (TEAEs), all of which were mild or moderate and consistent with previous safety data on Xywav. According to Dr. Kelvin Tan , Chief Medical Affairs Officer at Jazz Pharmaceuticals, the data add to the growing body of evidence supporting sodium reduction as a modifiable risk factor.
Delivered as a Hybrid Event. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).
VICTORIA, British Columbia–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc.
In order to listen to the audio webcast, interested parties can register and access the live webcast under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. 8, 2021 11:05 UTC.
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. Serious adverse events were somewhat lower in Dupixent (2%) than in omalizumab (4%).
A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.
Safety Profile and Tolerability: No Surprises, GI Events Mostly Mild In terms of safety, the Phase 2 study did not identify any new safety signals. The most common adverse events (AEs) reported were GI-related , including nausea and vomiting, and were generally mild to moderate in severity.
Case Study: How to Ensure Safety While Manufacturing Highly Potent APIs aasimakopoulos Mon, 11/04/2024 - 17:37 Highly potent active pharmaceutical ingredients (API) require careful attention to safety and handling during formulation and manufacturing.
There were no serious adverse events related to treatment and no clinically significant injection site reactions. About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding This event will be broadcast live on Friday, June 23, 2023, from 12:00 p.m. to 1:30 p.m.
Why do trade and channel professionals choose this pivotal event? To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net). The challenge of staying viable among shifting market dynamics while meeting business objectives is heavy. All rights reserved.
Delivered as a Hybrid Event. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).
By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.
1] [2] Adverse effects The US Food and Drug Administration prescription label for fitusiran contains a boxed warning for thrombotic events (blood clotting) and gallbladder disease (with some recipients requiring gallbladder removal). [2] Fitusiran 1711.0g/mol, 1] It is an antithrombin-directed small interfering ribonucleic acid. [1]
17, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” commented John Climaco , CEO of CNS Pharmaceuticals.
About CNS Pharmaceuticals, Inc.
Importantly, the therapy demonstrated a favorable safety profile, with no thromboembolic events reported so far. Engineered by Chugai Pharmaceutical Co., No thromboembolic events—an important safety consideration for all coagulation therapies—were reported.
You can access conference information and register for the event here. The presentation will also cover the legal, regulatory, and practical considerations involved throughout the reporting and enforcement process, including recent developments in state-level enforcement approaches and their impact on reporting and mitigation strategies.
As a proof of concept, a drug designed to target a newly discovered biological node is showing efficacy in treating rare genetic diseases in the kidney, the eye, and the brain and is now making its way to clinical trials in collaboration with a pharmaceutical partner. We will keep you in the loop on upcoming events and research highlights.
This annual event has become a must-attend for pricing and contracting professionals in the life sciences industry with seasoned leaders and forward-thinking strategies on display. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). NEW THIS YEAR! d/b/a Drug Channels Institute.
–( BUSINESS WIRE )– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. About Spectrum Pharmaceuticals, Inc.
Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.
Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. 4 patients (33%) had grade 4 adverse events. Importantly, effective combinatorial approaches that include these targets are emerging.
The technique has proven to be especially effective in addressing the unique barriers that adult learners often encounter, particularly while learning dense and complex material, such as that in pharmaceutical sales training. This blog will explore how gamification is positively impacting pharmaceutical sales training.
03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),
Delivered as a Hybrid Event In-Person: November 9-10 | Philadelphia, PA Virtual: November 16-17 www.informaconnect.com/drug-pricing-transparency. Choose how you attend with the All-Access Pass , registration to both the in-person and virtual events, or the Virtual-Only Pass. Informa Connect’s Drug Pricing Transparency Congress.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content